Abstract
ErbB3/HER3 belongs to the family of ErbB receptors, which comprises four transmembrane receptors that can bind more than ten different ligands. The ErbB3 receptor forms heterodimers with the other ErbB receptor family members, which is the necessary step to activate downstream prosurvival signaling. While ErbB3 signaling plays an important role in embryonic development, it has also been implicated in the development of cancer and in mediating resistance to anti-cancer treatments. In this chapter, we summarize the state of anti-ErbB3 therapies currently in clinical development including the emerging clinical data on HRG mRNA as a potential prognostic and predictive biomarker.
Author supplied keywords
Cite
CITATION STYLE
Lugovskoy, A., Curley, M., Lahdenranta, J., Kalra, A., Czibere, A., MacBeath, G., & Schoeberl, B. (2017). HER3. In Cancer Therapeutic Targets (Vol. 2–2, pp. 719–737). Springer New York. https://doi.org/10.1007/978-1-4419-0717-2_95
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
